A computational tool has accurately predicted a drug combination that inhibited triple-negative breast cancer in in vitro experiments. Researchers at the Icahn School of Medicine at Mount Sinai (NY, ...
After its founding in 1976, scientists at Genentech worked methodically toward the development of its first biotechnology product. It was nearly a decade later that the FDA approved Protropin, a ...
New Computational Model Matches Drugs to Protein Synthesis Disruptors in Hereditary Diseases, Cancer
Genetic diseases that result from truncated proteins can be targeted by so-called nonsense suppression therapies—drugs that prevent protein translation from terminating prematurely. A new ...
Bissan Al-Lazikani (left) is a Professor of Genomic Medicine and Director of Therapeutics Data Science at The University of Texas MD Anderson Cancer Center (Houston, TX, USA), where she heads an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback